A02925 | Pages: NA | Jul 2022 | 5466 Views | | |
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Recombinant Coagulation Factors Market
Request Now !Recombinant coagulation factors are plasma derived counterparts used to treat infection from viruses such as hepatitis C and the human immunodeficiency virus. In addition, recombinant coagulation factors have low risk for transmission of infectious agents.
Increase in number of hemophilia patients and rise in number of R&D on coagulation factors drive the market. However, high cost associated with hemophilia treatment and availability of alternative recombinant coagulation factors impede the market growth. Moreover, the expansion of the business in developing economies such as China, India, and Brazil create more lucrative opportunities for the market.
The global recombinant coagulation factors market is segmented based on product type, hemophilia type, end user, and geography. Based on product type, the market is classified into recombinant factor VIII, recombinant factor IX, and Von Willebrand factor. Based on hemophilia type, the market is divided into hemophilia A and hemophilia B. Based on end user, it is categorized into hospitals, clinics, and research organizations. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Baxter International Inc., Bayer AG, Biogen Idec, CSL Ltd., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, Octapharma AG, and Pfizer Inc. are also provided in this report.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 RECOMBINANT COAGULATION FACTORS MARKET, BY PRODUCT TYPE
4.1. OVERVIEW
4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast
4.2. RECOMBINANT FACTOR VIII
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. RECOMBINANT FACTOR IX
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. VON WILLEBRAND FACTOR
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 RECOMBINANT COAGULATION FACTORS MARKET, BY HEMOPHILIA TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HEMOPHILIA A
5.2.1. Market size and forecast
5.3. HEMOPHILIA B
5.3.1. Market size and forecast
CHAPTER 6 RECOMBINANT COAGULATION FACTORS MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. HOSPITALS
6.2.1. Market size and forecast
6.3. CLINICS
6.3.1. Market size and forecast
6.4. RESEARCH ORGANIZATIONS
6.4.1. Market size and forecast
CHAPTER 7 RECOMBINANT COAGULATION FACTORSMARKET, BY REGION
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast
7.2.4. North America Recombinant Coagulation Factors Market by Product Type
7.2.5. North America Recombinant Coagulation Factors Market by Hemophilia Type
7.2.6. North America Recombinant Coagulation Factors Market by End User
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Spain market size and forecast
7.3.3.5. Rest of Europe market size and forecast
7.3.4. Europe Recombinant Coagulation Factors Market By Product Type
7.3.5. Europe Recombinant Coagulation Factors Market By Hemophilia Type
7.3.6. Europe Recombinant Coagulation Factors Market By End User
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast
7.4.4. Asia Pacific Recombinant Coagulation FactorsMarket By Product Type
7.4.5. Asia Pacific Recombinant Coagulation FactorsMarket By Hemophilia Type
7.4.6. Asia Pacific Recombinant Coagulation FactorsMarket By End User
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast
7.5.4. LAMEA Recombinant Coagulation FactorsMarket By Product Type
7.5.5. LAMEA Recombinant Coagulation FactorsMarket By Hemophilia Type
7.5.6. LAMEA Recombinant Coagulation FactorsMarket By End User
CHAPTER 8 COMPANY PROFILES
8.1. BAXTER INTERNATIONAL INC.
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. BAYER AG
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. BIOGEN IDEC
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. CSL LTD.
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. GRIFOLS INTERNATIONAL SA
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. KEDRION S.P.A.
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. NOVO NORDISK A/S
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. OCTAPHARMA AG
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. PFIZER INC.
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers